Cited 0 times in

Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer

DC Field Value Language
dc.contributor.authorCho, O-
dc.contributor.authorChun, M-
dc.contributor.authorChang, SJ-
dc.contributor.authorOh, YT-
dc.contributor.authorNoh, OK-
dc.date.accessioned2018-05-04T00:26:10Z-
dc.date.available2018-05-04T00:26:10Z-
dc.date.issued2016-
dc.identifier.issn0250-7005-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/15098-
dc.description.abstractAIM: To investigate whether common terminology criteria for adverse events (CTCAE) grade 4 lymphopenia (<200 cells/mul) during concurrent chemoradiotherapy (CCRT) is relevant to poor survival. PATIENTS AND METHODS: We analyzed 124 patients with newly diagnosed Federation of Gynecology and Obstetrics (FIGO) stage I-III cervical cancer who received weekly cisplatin-based CCRT and brachytherapy using Kaplan-Meier curves and the Cox proportional hazard models. RESULTS: Grade 4 lymphopenia significantly predicted disease-specific survival (DSS) and progression-free survival (PFS) (adjusted hazard ratio (95% confidence interval (CI))=3.6 (1.37-9.44), p=0.009 and 3.28 (1.27-8.48), p=0.014, respectively). The 5-year DSS and 3-year PFS were significantly higher among patients with grade 2-3 lymphopenia (>/=200 cells/mul) than among those with grade 4 lymphopenia (84.8% vs. 50.4%, p<0.001, and 80.7% vs. 50%, p=0.002, respectively). CONCLUSION: Severe lymphopenia during CCRT could predict poor survival.-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use-
dc.subject.MESHBrachytherapy-
dc.subject.MESHChemoradiotherapy-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLymphopenia/diagnosis-
dc.subject.MESHLymphopenia/mortality-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultivariate Analysis-
dc.subject.MESHPrognosis-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHUterine Cervical Neoplasms/diagnosis-
dc.subject.MESHUterine Cervical Neoplasms/mortality-
dc.subject.MESHUterine Cervical Neoplasms/therapy-
dc.titlePrognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer-
dc.typeArticle-
dc.identifier.pmid27354621-
dc.identifier.urlhttp://ar.iiarjournals.org/cgi/pmidlookup?view=long&pmid=27354621-
dc.contributor.affiliatedAuthor조, 오연-
dc.contributor.affiliatedAuthor전, 미선-
dc.contributor.affiliatedAuthor장, 석준-
dc.contributor.affiliatedAuthor오, 영택-
dc.contributor.affiliatedAuthor노, 오규-
dc.type.localJournal Papers-
dc.citation.titleAnticancer research-
dc.citation.volume36-
dc.citation.number7-
dc.citation.date2016-
dc.citation.startPage3541-
dc.citation.endPage3547-
dc.identifier.bibliographicCitationAnticancer research, 36(7). : 3541-3547, 2016-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1791-7530-
dc.relation.journalidJ002507005-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Radiation Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Obstetrics & Gynecology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse